ALKBH8: A Potential Drug Target and Biomarker for ALS (G91801)

Target Name: ALKBH8

NCBI ID: G91801

ALKBH8

ALKBH8: A Potential Drug Target and Biomarker for ALS

Ammonium imidazole-induced neurodegeneration (AIN) is a progressive neurodegenerative disorder that is characterized by the progressive loss of motor neurons. The most common cause of AIN is the progressive motor neuron loss associated with ammonium imidazole (AIM), which is a neurotoxin that can cause damage to the nervous system.

Several factors contribute to the development and progression of AIN, including genetic and environmental factors. The tRNA (carboxymethyluridine(34)-5-O)-methyltransferase (ALKBH8) gene has been identified as a potential drug target and biomarker for AIN.

The Story of ALKBH8

ALKBH8 is a gene that encodes a protein known as ALKBH8, which is a key enzyme involved in the transfer of methyl groups to specific locations on the DNA. The ALKBH8 gene was identified as a potential drug target for AIN due to its involvement in the pathophysiology of the disease.

Studies have shown that AIN is associated with the expression of misfolded proteins, including the neurotoxin AIM. The misfolded proteins can cause structural changes in the DNA that lead to the formation of reactive oxygen species (ROS), which can contribute to the development of AIN.

ALKBH8 plays a key role in the regulation of the expression of misfolded proteins, as it is involved in the transfer of methyl groups to specific locations on the DNA. By modifying the expression of misfolded proteins, ALKBH8 can potentially contribute to the development and progression of AIN.

Potential Therapeutic Strategies

The discovery of ALKBH8 as a potential drug target for AIN has led to the development of several potential therapeutic strategies.

1. ALKBH8 inhibition: One approach to targeting ALKBH8 is to inhibit its activity, potentially by using small molecules or antibodies that bind to the protein. This approach would be useful if ALKBH8 is a validated drug target, and if available compounds can be found that inhibit its activity.
2. ALKBH8 modulation: Another approach to targeting ALKBH8 is to modify its expression levels. This could be done using techniques such as RNA interference or CRISPR/Cas9 genome editing to knockdown or up the expression of ALKBH8. This approach would be useful if the underlying mechanism of AIN is not well understood, or if it is difficult to target ALKBH8 directly.
3. ALKBH8 targeting: A third approach to targeting ALKBH8 is to use antibodies or other biomarkers to specifically target the protein in the AIN patient. This approach would be useful if the goal is to measure the level of ALKBH8 in the patient's tissues or cells, or if it is necessary to monitor the effectiveness of a therapeutic intervention.

Conclusion

The discovery of ALKBH8 as a potential drug target and biomarker for AIN has significant implications for the development of new therapeutic strategies for this progressive neurodegenerative disorder. Further research is needed to fully understand the role of ALKBH8 in the pathophysiology of AIN and to develop effective treatments.

Protein Name: AlkB Homolog 8, TRNA Methyltransferase

Functions: Catalyzes the methylation of 5-carboxymethyl uridine to 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its methyltransferase domain (PubMed:20123966, PubMed:20308323, PubMed:31079898). Catalyzes the last step in the formation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in target tRNA (PubMed:20123966, PubMed:20308323). Has a preference for tRNA(Arg) and tRNA(Glu), and does not bind tRNA(Lys)(PubMed:20308323). Binds tRNA and catalyzes the iron and alpha-ketoglutarate dependent hydroxylation of 5-methylcarboxymethyl uridine at the wobble position of the anticodon loop in tRNA via its dioxygenase domain, giving rise to 5-(S)-methoxycarbonylhydroxymethyluridine; has a preference for tRNA(Gly) (PubMed:21285950). Required for normal survival after DNA damage (PubMed:20308323). May inhibit apoptosis and promote cell survival and angiogenesis (PubMed:19293182)

The "ALKBH8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALKBH8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets